Investigational COVID-19 Convalescent Plasma

On 7 January 2022 the FDA published the final guidance for industry.

FDA is issuing this guidance to provide recommendations to health care providers and investigators on the use of COVID-19 convalescent plasma or investigational convalescent plasma during the public health emergency. The guidance also provides recommendations to blood establishments on collection. This document supersedes the guidance of the same title issued in February 2021 (previous versions January 2021, November 2020, September 2020, May 2020, and April 2020).

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /